This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
Female
Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer
Premenopausal
In active treatment (including long-term endocrine therapy) at the time of enrollment
Individuals under age 18 or over age 50 at initial breast cancer diagnosis
Patients with breast cancer who are not being treated with ET
Stage IV or metastatic breast cancer
Pregnant patients
Dana-Farber Cancer Institute
Lead sponsor
Breast Cancer Research Foundation
Collaborator